1. NCCU Academic Hub
  2. 學術產出
  3. 商學院
  4. 期刊論文
  5. Item

學術產出-期刊論文

文章檢視/開啟

書目匯出

Google ScholarTM

政大圖書館

引文資訊

TAIR相關學術產出

題名 How can small firms benefit from open innovation? The case of new drug development in Taiwan
作者 吳豐祥
Su, Yu-Shan;Hu, Hsin-Yi;Wu, Feng-Shang
貢獻者 科管智財所
關鍵詞 open innovation, small firms, external partners, new drug development, Taiwan, biotechnology firms, new drugs, biotech firms, drug discovery, technology transfer, drug licensing, technology acquisition
日期 2016-01
上傳時間 28-六月-2017 15:17:12 (UTC+8)
摘要 How can small firms manage and benefit from open innovation? We study three Taiwan`s biotechnology firms leveraging open innovation in developing new drugs. At the phase of the new drug discovery, two companies acquired technology from external sources. CSRC Synpac Company acquired technology from Professor Yuan-Tsong Chen at Duke University (USA) in 1991. GlycoNex Company acquired technology from Professor Sen-itiroh Hakomori at University of Washington (USA) in 2001. AbGenomics Company developed its own technology at Professor Rong-Hwa Lin`s team at National Taiwan University (Taiwan) in 2000. Through technology transfer, CSRC Synpac Company licensed out the new drug Myozyme to Genzyme Corporation (USA) in 2000. AbGenomics Company licensed out the new drug AbGn-168H to Boehringer Ingelheim Pharmaceutical (Germany) in 2005. GlycoNex Company licensed out the new drug GNX-8 to Otsuka Pharmaceutical (Japan) in 2009.
關聯 International Journal of Technology Management, 72(1-3), 61-83
資料類型 article
DOI http://dx.doi.org/10.1504/IJTM.2016.080551
dc.contributor 科管智財所
dc.creator (作者) 吳豐祥zh_TW
dc.creator (作者) Su, Yu-Shan;Hu, Hsin-Yi;Wu, Feng-Shang
dc.date (日期) 2016-01
dc.date.accessioned 28-六月-2017 15:17:12 (UTC+8)-
dc.date.available 28-六月-2017 15:17:12 (UTC+8)-
dc.date.issued (上傳時間) 28-六月-2017 15:17:12 (UTC+8)-
dc.identifier.uri (URI) http://nccur.lib.nccu.edu.tw/handle/140.119/110546-
dc.description.abstract (摘要) How can small firms manage and benefit from open innovation? We study three Taiwan`s biotechnology firms leveraging open innovation in developing new drugs. At the phase of the new drug discovery, two companies acquired technology from external sources. CSRC Synpac Company acquired technology from Professor Yuan-Tsong Chen at Duke University (USA) in 1991. GlycoNex Company acquired technology from Professor Sen-itiroh Hakomori at University of Washington (USA) in 2001. AbGenomics Company developed its own technology at Professor Rong-Hwa Lin`s team at National Taiwan University (Taiwan) in 2000. Through technology transfer, CSRC Synpac Company licensed out the new drug Myozyme to Genzyme Corporation (USA) in 2000. AbGenomics Company licensed out the new drug AbGn-168H to Boehringer Ingelheim Pharmaceutical (Germany) in 2005. GlycoNex Company licensed out the new drug GNX-8 to Otsuka Pharmaceutical (Japan) in 2009.
dc.format.extent 1011675 bytes-
dc.format.mimetype application/pdf-
dc.relation (關聯) International Journal of Technology Management, 72(1-3), 61-83
dc.subject (關鍵詞) open innovation, small firms, external partners, new drug development, Taiwan, biotechnology firms, new drugs, biotech firms, drug discovery, technology transfer, drug licensing, technology acquisition
dc.title (題名) How can small firms benefit from open innovation? The case of new drug development in Taiwan
dc.type (資料類型) article
dc.identifier.doi (DOI) 10.1504/IJTM.2016.080551
dc.doi.uri (DOI) http://dx.doi.org/10.1504/IJTM.2016.080551